Subscribe To
Morphic announces corporate highlights and financial results for the third quarter 2023
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative...
November 3, 2023, 11:00 am
Pfizer's coming for abbvie's market share. here's what it means for investors
Pfizer just got an approval for a drug to treat ulcerative colitis. AbbVie is still trying to consolida...
October 31, 2023, 10:07 am
Roche, lilly or pfizer: who's the winner in ibd wars?
Roche spent $7.1 billion on a company, primarily because of an IBD therapy. Pfizer just got approval for a pill to treat ...
October 28, 2023, 8:45 am
Peptic ulcer drugs market projected to surge to us$59.2 billion by 2033, fueled by otc adoption and phytotherapy emergence: report by persistence market research
In 2022, the United States dominated the North American market, securing a substantial market share of approximately 85.3%. The prevalence of peptic <...
October 25, 2023, 8:39 am
Roche enters into a definitive agreement to acquire telavant including rights to novel tl1a directed antibody (rvt-3101) for the treatment of inflammatory bowel disease from roivant
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and ...
October 23, 2023, 5:00 am
Spectral ai expands diabetic foot ulcer study to additional clinical sites
Spectral AI Inc (NASDAQ:MDAI) announced it has added seven clinical sites to its multi-centre study of its DeepView Wound Imaging System for diabetic ...
October 16, 2023, 8:45 am
U.s. fda approves pfizer's inflammatory bowel disease drug
Pfizer said on Friday that theU.S. Food and Drug Administration has approved its drug to treat adults with moderate-to-severe inflammatory bowel disea...
October 13, 2023, 9:09 am
Ventyx (vtyx) down despite positive ulcerative colitis study data
Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-s...
October 11, 2023, 12:47 pm
What you need to know about the ulcer index
In stock trading and investment, accurately assessing risk is paramount for long-term success. Among the myriad metrics and indicators available to in...
October 11, 2023, 3:31 am
Why shares of ventyx biosciences are dropping tuesday
Ventyx is a clinical-stage biotech that focuses on autoimmune disorders. The company's lead therapy candidate is VTX002 to treat moderate-to-severe ...
October 10, 2023, 12:55 pm
Sanofi to co-develop teva pharmaceutical's colitis, crohn's drug
Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ...
October 4, 2023, 3:15 am
Morphic to present positive emerald-1 phase 2a data for morf-057 in patients with moderate to severe ulcerative colitis in abstract for uegw 2023
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-...
September 22, 2023, 9:30 pm
Morphic to present positive emerald-1 phase 2a data for morf-057 in patients with moderate to severe ulcerative colitis in abstract for uegw 2023
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-...
September 22, 2023, 5:30 pm
: bruce springsteen postpones september tour dates, citing illness
Bruce Springsteen and the E Street Band postponed all of their September tour dates Wednesday night, saying the iconic singer/songwriter is being trea...
September 7, 2023, 1:12 am
Morphic announces corporate highlights and financial results for the second quarter 2023
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued e...
August 3, 2023, 11:05 am
Teva pharmaceutical's remarkable growth in 2023: a success story
On August 2, 2023, Teva Pharmaceutical, one of the world's top generic drug manufacturers, will publish its financial report for the second quarter of...
July 20, 2023, 10:43 am
Roivant in talks to sell bowel disease drug to roche in over $7 bln deal - wsj
Biotech company Roivant Sciences is nearing a deal to sell an experimental drug to treat inflammatory bowel diseases including ...
July 13, 2023, 6:28 pm
After ‘transformative' year, roivant aims to challenge bigger rivals in inflammation and immunology
After surviving some turbulent market conditions in its first years as a public company, Roivant Sciences Ltd. ROIV, +10.77% is taking on industry beh...
June 28, 2023, 3:40 pm
Why roivant sciences stock is perking up today
Roivant Sciences announced positive long-term data for its midstage ulcerative colitis drug. Investors ...
June 22, 2023, 11:41 am
Roivant sciences shares gain after ulcerative colitis treatment shows longer-term results
Shares of Roivant Sciences Ltd. ROIV, -2.66% gained 14% in premarket trading Thursday after the company released new long-duration data from a study o...
June 22, 2023, 8:09 am